Phoenix Biotech (PBAX) to Combine with Intrinsic Medicine in $207M Deal

Oct 31, 2022 Deal Announcements & Amendments, Headline Post, INTEL by Marlena Haddad

Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) has entered into a definitive agreement to combine with preclinical-stage therapeutics company Intrinsic Medicine, Inc. at an enterprise value of $207.3 million. The Seattle, Washington-based company is a preclinical-stage therapeutics firm leveraging synthetic biology-manufactured human milk oligosaccharides (HMOs) to help treat gut-brain axis disorders (GBA). The combined company is expected
Read More

To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.

Phoenix Biotech (PBAX) to Combine with Intrinsic Medicine in $207M Deal

Phoenix Biotech (PBAX) to Combine with Intrinsic Medicine in $207M Deal

ByMarlena Haddad